For new medical technologies to be adopted in over-burdened systems like the NHS, proof of efficacy in a lab is insufficient. The 'real acid test' is demonstrating that the technology works on the front lines of a busy, complex hospital. This real-world evidence is essential for gaining buy-in from skeptical staff.

Being patient-centered is necessary but insufficient for adoption. Technology in healthcare must be seamlessly embedded into a physician's existing, time-constrained workflow. Great tech that adds friction will be ignored, regardless of its potential patient benefit.

Product stickiness in health systems is achieved through deep workflow integration. By embedding a solution into the daily processes of every stakeholder—from medical assistants to billing coordinators—it becomes entrenched and difficult to replace, mirroring the zero-churn model of EMR giant Epic.

While SmallTap's higher clinical success rate is key, its adoption is driven by benefits to multiple stakeholders. The messaging highlights reduced physical strain on nurses, lower stress for doctors, and a clear financial ROI for hospitals by avoiding unnecessary admittances.

Proving the ROI of clinical AI can take years if based solely on patient outcomes. Instead, focus on early, measurable operational wins that are known proxies for better care. Track metrics like increased clinician capacity and higher patient engagement rates to prove the system's value and build momentum.

In healthcare, the user, recommender, and payer are often different entities. A clinically effective product can easily fail if it's not inserted into the right point in the value chain where a stakeholder is both willing and incentivized to pay for it.

To gain physician trust, AI companies must move beyond proving their algorithm is accurate. The gold standard is large-scale clinical evidence demonstrating tangible improvements in patient outcomes, treatment rates, and decision-making speed.

The successful early adoption of AI in healthcare was brilliant because it first targeted the administrative burdens that clinicians hate, such as documentation (scribes) and billing. By winning the hearts and minds of powerful incumbents with immediate quality-of-life improvements, the industry built momentum for more complex clinical applications.

Strong data from controlled trials will open doors, but it won't guarantee broad adoption. True success comes from a product's predictable, reliable performance in everyday clinical settings, which are far more chaotic than an investigational site.